Erudio Healtherudio.com
Clinical trial · no report yet · Phase 2
NCT02899052 trial: what clinicians have said so far
Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma (MM)
- NCT02899052 ↗
- Active, not recruiting
- AbbVie
- Focused size, estimated: 1–150 verified statements
We haven't built an HCP commentary report on NCT02899052 yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on NCT02899052 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 3 posts on X |
The trial
ClinicalTrials.gov- Official title
- A Phase 2, Open-Label, Multi-Center Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
- Phase
- Phase 2
- Status
- Active, not recruiting
- Conditions
- Multiple Myeloma
- Interventions
- Carfilzomib; Venetoclax; Dexamethasone
- Arms
- Venetoclax + Carfilzomib + Dexamethasone · Experimental
- Enrollment
- 120 (estimated)
- Primary outcomes
- Number of Participants with Adverse Events
- Very Good Partial Response (VGPR) or Better Response Rate of VenKd in Participants with Relapsed or Refractory Multiple Myeloma (RRMM) as well as Those with t(11;14)-positive RRMM
- Objective Response Rate (ORR) of VenKd in Participants with Relapsed or Refractory Multiple Myeloma (RRMM) as well as Those with t(11;14)-positive RRMM
- Complete Response (CR) or Better Rate of VenKd in Participants with Relapsed or Refractory Multiple Myeloma (RRMM) as well as Those with t(11;14)-positive RRMM
- Sponsor
- AbbVie with Genentech, Inc; Onyx Therapeutics, Inc.
- Start
- Jan 19, 2017
- Primary completion
- Jun 2027 (estimated)
- Results posted
- No
- Registry record
- NCT02899052 · updated Aug 5, 2025
Publications
linked from the registry- Badawi MA, Engelhardt B, Dobkowska E, Deng R, Kaufman JL, Menon R, Salem AH. Exposure-response relationships of venetoclax in combination with carfilzomib and dexamethasone in relapsed/refractory t(11;14) multiple myeloma patients. Invest New Drugs. 2024 Dec;42(6):635-643. doi: 10.1007/s10637-024-01471-x. Epub 2024 Oct 10. PubMed 39388024
- Costa LJ, Davies FE, Monohan GP, Kovacsovics T, Burwick N, Jakubowiak A, Kaufman JL, Hong WJ, Dail M, Salem AH, Yang X, Masud AA, Munasinghe W, Ross JA, Bueno OF, Kumar SK, Stadtmauer EA. Phase 2 study of venetoclax plus carfilzomib and dexamethasone in patients with relapsed/refractory multiple myeloma. Blood Adv. 2021 Oct 12;5(19):3748-3759. doi: 10.1182/bloodadvances.2020004146. PubMed 34470049